Scholar Rock (SRRK) Projected to Post Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $34.60 on Friday. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The firm has a 50 day moving average of $39.46 and a 200-day moving average of $31.34. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -14.72 and a beta of 0.59.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SRRK. HC Wainwright increased their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial raised their price objective on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Finally, Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a research note on Wednesday, January 29th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $40.43.

Insider Transactions at Scholar Rock

In other Scholar Rock news, CEO Jay T. Backstrom sold 18,372 shares of Scholar Rock stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $676,640.76. Following the completion of the transaction, the chief executive officer now owns 311,991 shares of the company’s stock, valued at $11,490,628.53. The trade was a 5.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now directly owns 111,345 shares of the company’s stock, valued at $3,966,108.90. The trade was a 56.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 292,266 shares of company stock worth $10,996,151 in the last ninety days. Company insiders own 19.20% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.